

Joy Y Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9497074/publications.pdf>

Version: 2024-02-01

56
papers

10,474
citations

126907

33
h-index

161849

54
g-index

61
all docs

61
docs citations

61
times ranked

12335
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. <i>Nature Communications</i> , 2020, 11, 222.	12.8	1,376
2	Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	1,279
3	Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. <i>Nature</i> , 2016, 531, 381-385.	27.8	1,245
4	Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. <i>MBio</i> , 2018, 9, .	4.1	1,142
5	Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. <i>Journal of Biological Chemistry</i> , 2020, 295, 6785-6797.	3.4	752
6	The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. <i>Journal of Biological Chemistry</i> , 2020, 295, 4773-4779.	3.4	659
7	Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- <i>f</i>][triazin-4-amino] Adenine <i>C</i> -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1648-1661.	6.4	547
8	Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. <i>Viruses</i> , 2019, 11, 326.	3.3	478
9	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	6.4	412
10	Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. <i>Antiviral Research</i> , 2019, 169, 104541.	4.1	398
11	Structural basis for RNA replication by the hepatitis C virus polymerase. <i>Science</i> , 2015, 347, 771-775.	12.6	294
12	Synthesis and antiviral activity of a series of 1- ϵ -substituted 4-aza-7,9-dideazaadenosine C-nucleosides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2705-2707.	2.2	173
13	Mechanistic Studies Examining the Efficiency and Fidelity of DNA Synthesis by the 3TC-Resistant Mutant (184V) of HIV-1 Reverse Transcriptase. <i>Biochemistry</i> , 1999, 38, 9440-9448.	2.5	123
14	Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. <i>Journal of Biological Chemistry</i> , 2020, 295, 16156-16165.	3.4	120
15	Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides. <i>PLoS Pathogens</i> , 2012, 8, e1003030.	4.7	119
16	Discovery of the First <i>C</i> -Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1812-1825.	6.4	108
17	Mechanism of Action of 1- β -d-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1- β -d-Dioxolane Guanosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 158-165.	3.2	81
18	Mechanistic Studies Comparing the Incorporation of (+) and ($\hat{\alpha}$) Isomers of 3TCTP by HIV-1 Reverse Transcriptase. <i>Biochemistry</i> , 1999, 38, 55-63.	2.5	78

#	ARTICLE	IF	CITATIONS
19	Relationship between Antiviral Activity and Host Toxicity: Comparison of the Incorporation Efficiencies of 2'-,3'-Dideoxy-5-Fluoro-3'-Thiacytidine-Triphosphate Analogs by Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Human Mitochondrial DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1300-1306.	3.2	71
20	The K65R Reverse Transcriptase Mutation in HIV-1 Reverses the Excision Phenotype of Zidovudine Resistance Mutations. <i>Antiviral Therapy</i> , 2006, 11, 155-163.	1.0	69
21	Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 806-817.	3.2	68
22	Mechanistic studies show that (â'')â€¦FTCâ€¦TP is a better inhibitor of HIVâ€¦ reverse transcriptase than 3TCâ€¦TP. <i>FASEB Journal</i> , 1999, 13, 1511-1517.	0.5	66
23	The A62V and S68G Mutations in HIV-1 Reverse Transcriptase Partially Restore the Replication Defect Associated With the K65R Mutation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 428-436.	2.1	58
24	Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129531.	2.4	57
25	The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. <i>Retrovirology</i> , 2009, 6, 44.	2.0	56
26	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. <i>Science Translational Medicine</i> , 2022, 14, eabm3410.	12.4	49
27	Addressing the selectivity and toxicity of antiviral nucleosides. <i>Antiviral Chemistry and Chemotherapy</i> , 2018, 26, 204020661875852.	0.6	45
28	Inhibition of Hepatitis C Virus Replication by GS-6620, a Potent <i>C</i>-Nucleoside Monophosphate Prodrug. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1930-1942.	3.2	38
29	Off-Target <i>In Vitro</i> Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	38
30	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021, 36, 109450.	6.4	38
31	Synthesis and characterization of 2'-C-Me branched C-nucleosides as HCV polymerase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4127-4132.	2.2	37
32	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0060221.	3.2	37
33	In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4387-4394.	3.2	35
34	The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. <i>Antiviral Therapy</i> , 2006, 11, 155-63.	1.0	34
35	Dioxolane Guanosine 5'-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase. <i>Journal of Biological Chemistry</i> , 2003, 278, 18971-18979.	3.4	32
36	Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006, 25, 89-107.	1.1	25

#	ARTICLE	IF	CITATIONS
37	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. <i>Journal of Biological Chemistry</i> , 2022, 298, 101529.	3.4	25
38	Discovery of 2'-deoxy-2'-fluoro-4'-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2484-2487.	2.2	23
39	Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5'-phosphates by mammalian phosphotransferases. <i>Biochemical Pharmacology</i> , 2004, 68, 1879-1888.	4.4	20
40	Nucleoside Diphosphate Kinase and the Activation of Antiviral Phosphonate Analogs of Nucleotides: Binding Mode and Phosphorylation of Tenofovir Derivatives. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 776-792.	1.1	18
41	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
42	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. <i>FASEB Journal</i> , 2001, 15, 1902-1908.	0.5	13
43	Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 358-364.	2.8	11
44	Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs. <i>PLoS ONE</i> , 2017, 12, e0185998.	2.5	10
45	Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. <i>Antiviral Research</i> , 2014, 101, 131-135.	4.1	9
46	The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2. <i>Molecules</i> , 2022, 27, 4212.	3.8	9
47	Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (2'-d-1,3-dioxolan guanine. <i>Antiviral Research</i> , 2005, 66, 153-158.	4.1	7
48	Discovery of a 2'-fluoro-2'-C -methyl C -nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1840-1847.	2.2	7
49	Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity. <i>Toxicological Sciences</i> , 2017, 155, 2-2.	3.1	7
50	Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	6
51	HCV RdRp, sofosbuvir and beyond. <i>The Enzymes</i> , 2021, 49, 63-82.	1.7	5
52	Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Endonuclease activity and evaluation of inhibitors. <i>PLoS ONE</i> , 2017, 12, e0181969.	2.5	4
53	Reply to Yan and Muller, "Remdesivir for COVID-19: Why Not Dose Higher?". <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	2
54	Species-Specific Urothelial Toxicity With an Anti-HIV Noncatalytic Site Integrase Inhibitor (NCINI) Is Related to Unusual pH-Dependent Physicochemical Changes. <i>Toxicological Sciences</i> , 2021, 183, 105-116.	3.1	1

#	ARTICLE	IF	CITATIONS
55	Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 416-424.	4.7	1
56	Reply to Yan and Muller, "Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver". <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0139421.	3.2	0